Terlipressin Linked to Lower In-Hospital Mortality in HRS-AKI
This retrospective cohort offers real-world in-hospital mortality and renal-response data comparing terlipressin against the midodrine-octreotide standard for hepatorenal syndrome-acute kidney injury (HRS-AKI), a gap the pivotal registration trial did not directly address.
Terlipressin shows promise in lowering HRS-AKI mortality compared to standard treatments.
Terlipressin, a vasopressin analogue, has shown potential benefits for hepatorenal syndrome-acute kidney injury (HRS-AKI) in terms of mortality and renal function improvement. In-hospital mortality was significantly lower with terlipressin (24.5%) compared to midodrine and octreotide (70%). Terlipressin also led to a quicker reduction in serum creatinine levels. The study suggests terlipressin may be more effective than midodrine and octreotide for initial treatment of HRS-AKI. Limitations include the single-center, retrospective design and small sample size. Terlipressin may reduce in-hospital mortality for HRS-AKI more effectively than midodrine and octreotide.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Citation:Johnson HN, Juang PA Evaluation of Terlipressin and In-Hospital Mortality in the Treatment of Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI). The Annals of pharmacotherapy. 2026:10600280261467017. doi:10.1177/10600280261467017
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.